|
|
|
Synovial Sarcoma
Synovial sarcoma (SS) is a soft tissue sarcoma. Soft tissue sarcomas are malignant tumors of non-epithelial, extraskeletal tissue of the body, including the muscle, fat, fibrous tissue, vessels and peripheral nervous system. They form a diverse group of mesenchymal malignancies, classified on a histologic basis according to the adult tissue they resemble or are supposed to derive from. These tumors are rare. With an annual incidence of around 2-3/100,000, they account for less than 1% of all malignant tumors and 2% of all cancer-related deaths, although in children soft tissue sarcomas represent about 8% of all malignancies. SS represents one of the most frequent malignant tumors of soft tissues, accounting for about 8% of all soft tissue sarcomas. SS is the most frequent non-rhabdomyosarcomatous soft tissue sarcoma in adolescents and young adults, accounting for 15-20% of cases. The peak of incidence is in the 3rd decade (approximately 30% of cases occur in patients less than twenty years of age), and males are affected more often than females (male/female ratio around 1.2:1). Dr. Andrea Ferrari and Dr. Paolo Collini of the stituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy have written a detailed overview of SS for the Electronic Sarcoma Update Newsletter. Click here to view their article. It contains an extensive set of references on SS.
There are over 50 subtypes of sarcoma. The American Cancer Society's Key Statistics About Sarcoma states that the most common types of soft tissue sarcoma are: MFH or Malignant Fibrous Histiocytoma (28%), liposarcoma (15%), LMS or leiomyosarcoma (12%), synovial sarcoma (10%), malignant peripheral nerve sheath tumors (6%), and rhabdomyosarcoma (5%). All of the other types of soft tissue sarcoma occur at percentages of 3% or less. The ACS' Key Statistics for Bone Cancer states that the most common types of bone cancer are osteosarcoma (35%), chondrosarcoma (26%), Ewing's bone sarcoma (16%), chordoma (8%), and malignant fibrous histiocytoma/fibrosarcoma (6%). Other rare bone cancers account for the remaining 9%.
|
|